Regeneron Pharmaceuticals Inc. closed $66.17 short of its 52-week high ($1,211.20), which the company reached on August 27th.

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

The likely unification of Ireland will mean a greater economic role for the west but we need to plan for development like the ...

The Family and Medical Leave Act does not require employers to allow qualified employees to work remotely. While such ...

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

Dupilumab significantly reduced severe asthma exacerbations and SCS prescriptions vs omalizumab in patients using add-on maintenance therapy.

AZ and Regeneron will collaborate on finding small-molecule drugs directed against the GPR75 target, splitting the costs of the programme and sharing any resulting profits from the endeavour.

However, he sees opportunities outside of the GLP-1 landscape, pointing specifically to Regeneron (REGN) and Vertex (VRTX) as prime examples. Vertex, a leader in cystic fibrosis research, makes up ...

Roche RHHBY announced positive top-line results from a late-study on influenza drug, Xofluza. The CENTERSTONE study was a global phase III trial investigating the efficacy of single-dose Xofluza, ...

However, he sees opportunities outside of the GLP-1 landscape, pointing specifically to Regeneron (REGN) and Vertex (VRTX) as prime examples. Vertex, a leader in cystic fibrosis research, makes up ...